Present and future of developmental neuropsychopharmacology

Arango, Celso

doi:10.1016/j.euroneuro.2014.11.003

Cited by 16 publications

(6 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While very few studies have been carried out on this population, and most of the effects and proposed mechanisms are similar to those reported in adults, we believe that this population has increased risk for long-term microbiome changes and metabolic effects up to adulthood. The use of atypical antipsychotic drugs (also known as second-generation antipsychotics, or SGAs) has increased in the pediatric population, especially within the last decade, because of their effectiveness and much lower rates of extrapyramidal side effects compared with older generation drugs [3–5]. The effects of SGAs on the gut microbiome are specifically of interest because both these factors are known to affect metabolism and weight gain [6].…”

Section: Introductionmentioning

confidence: 99%

The effects of antipsychotic medications on microbiome and weight gain in children and adolescents

Bretler

Weisberg

Koren

et al. 2019

BMC Med

View full text Add to dashboard Cite

Background Atypical antipsychotics, also known as second-generation antipsychotics, are commonly prescribed as treatment for psychotic disorders in adults, as well as in children and adolescents with behavioral problems. However, in many cases, second-generation antipsychotics have unwanted side effects, such as weight gain, potentially further increasing risk for morbidities including obesity, diabetes, and cardiovascular disease. While various mechanisms for this weight gain have been proposed, including effects on metabolic hormone signaling, recent evidence points to the importance of the gut microbiome in this process. The microbial communities residing within the gut are affected by second-generation antipsychotics and can confer weight gain. Main text This review summarizes recent findings and presents data linking second-generation antipsychotics, gut microbiota alterations and weight gain. The review focuses on children and adolescent populations, which have not previously received much attention, but are of great interest because they may be most vulnerable to gut microbiome changes and may carry long-term metabolic effects into adulthood. Conclusions We present correlations between second-generation antipsychotics, gut microbiota alterations and weight gain, and suggest some mechanisms that may link them. A better understanding of the underlying mechanisms may lead to the design of improved treatments for psychotic disorders with fewer harmful side effects.

show abstract

Section: Introductionmentioning

confidence: 99%

The effects of antipsychotic medications on microbiome and weight gain in children and adolescents

Bretler

Weisberg

Koren

et al. 2019

BMC Med

View full text Add to dashboard Cite

show abstract

“…The off-label use of medicines for children and adolescents remains a common and important issue for prescribing practice across child and adolescent psychiatry, paediatrics and primary care (Arango, 2015; Persico et al, 2015). The issues regarding off-label use of drugs in neonates, infants, children younger than two years old and children with chronic and/or rare diseases are particularly complex and lie outside the scope of this position statement.…”

Section: Introductionmentioning

confidence: 99%

BAP Position Statement: Off-label prescribing of psychotropic medication to children and adolescents

et al. 2016

Self Cite

View full text Add to dashboard Cite

The off-label use of medicines for children and adolescents remains a common and important issue for prescribing practice across child and adolescent psychiatry, paediatrics and primary care. This editorial focusses on psychotropic drug treatment, which plays an essential part in the comprehensive management of a range of child and adolescent psychiatric disorders. Despite a growing evidence base for drug treatment in child and adolescent psychiatric disorders, much psychotropic medication continues to be prescribed off-label (i.e. outside the limits of the marketing authorisation or product license). The reasons for and implications of off-label prescribing, including the potential clinical benefits/risks and medico-legal implications, are often poorly understood by both patients and prescribers. An important unintended consequence of the uncertainties and confusion surrounding the status of off-label prescribing for children and adolescents may be that effective drug treatments are being withheld or underused. This BAP Position Statement aims to clarify these issues, challenge some of the myths surrounding off-label prescribing for children and adolescents and offer practical guidance for prescribers.

show abstract

“…Developmental neuropsychopharmacology has progressively evolved from considering youth as "small adults", to investigating new fields of interest specific to children and adolescents (Arango, 2015). However, to date only very few medications have been approved in Europe for use in children and adolescents (Table 2).…”

Section: The Off-label Prescription To Children and Adolescents Of Mementioning

confidence: 99%

Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives

Persico

Arango

Buitelaar

et al. 2015

European Neuropsychopharmacology

Self Cite

View full text Add to dashboard Cite

Present and future of developmental neuropsychopharmacology

Cited by 16 publications

References 79 publications

The effects of antipsychotic medications on microbiome and weight gain in children and adolescents

The effects of antipsychotic medications on microbiome and weight gain in children and adolescents

BAP Position Statement: Off-label prescribing of psychotropic medication to children and adolescents

Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives

Contact Info

Product

Resources

About